Whole Body Nitrogen Kinetics and Their Relationship to Growth in Short Children Treated with Recombinant Human Growth Hormone

Dempsher, D.; Bier, Dennis M.; Tollefsen, Sherida E.; Rotwein, Peter; Daughaday, William H.; Jensen, Mary Catherine; Galgani, John P.; Heath-Monnig, E.; Trivedi, Bakula

doi:10.1203/00006450-199010000-00018

Cited by 13 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum and plasma from 37 prepubertal children between the ages of 4.2 and 13.8 y and > 2 SD below the mean height for age were tested for their ability to immunoprecipitate purified 1251-labeled IGF-I receptor. Samples had been collected before the treatment protocol described previously (8). Figure 3A shows the mean percentage of '251-labeled IGF-I receptor immunoprecipitated by 1: 10 dilutions of serum or plasma samples from each patient.…”

Section: Resultsmentioning

confidence: 99%

Low Prevalence of Autoantibodies to the Insulin-like Growth Factor I Receptor in Children with Short Stature

et al. 1992

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Low Prevalence of Autoantibodies to the Insulin-like Growth Factor I Receptor in Children with Short Stature

et al. 1992

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is also now abundantly clear that growth hormone administration can increase the height velocity of short, slowly growing children who are not growth hormone deficient by conventional criteria (60)(61)(62)(63)(64)(65)(66)(67)(68)(69). When administered in doses estimated to be approximately two to three times the secretion rate (70,71), recombinant human growth hormone treatment results in an approximate doubling of height velocity from a pretreatment rate of about 4 to 4.5 cm/yr to a value of 8 and 9 cm/yr after six to twelve months of treatment (60)(61)(62)(63)(64)(65)(66)(67)(68)(69). At least acutely, this effect is the result of an increased protein turnover which, since synthesis is augmented more than breakdown, results in a net protein anabolic response (69).…”

Section: Therapeutic Potentialmentioning

confidence: 99%

“…When administered in doses estimated to be approximately two to three times the secretion rate (70,71), recombinant human growth hormone treatment results in an approximate doubling of height velocity from a pretreatment rate of about 4 to 4.5 cm/yr to a value of 8 and 9 cm/yr after six to twelve months of treatment (60)(61)(62)(63)(64)(65)(66)(67)(68)(69). At least acutely, this effect is the result of an increased protein turnover which, since synthesis is augmented more than breakdown, results in a net protein anabolic response (69). In addition, there is now ample evidence that growth hormone treatment can augment the growth velocities of chiidren with Turner syndrome (72,73) and of children with the pronounced growth arrest accompanying chronic renal failure (74)(75)(76).…”

Section: Therapeutic Potentialmentioning

confidence: 99%

“…Because growth hormone administration also increases energy expenditure (83)(84)(85), the availability of additional dietary energy may also be required. However, short term growth hormone treatment has produced rather dramatic net anabolic effects in children whose dietary protein and energy intakes did not change during the growth hormone administration (69,82). Furthermore, appetite must be sufficient to meet energy demands.…”

Section: Hypothesismentioning

confidence: 99%

See 1 more Smart Citation

Growth Hormone and Insulin‐Like Growth Factor I: Nutritional Pathophysiology and Therapeutic Potential

Bier

1991

Acta Paediatrica

View full text Add to dashboard Cite

Growth hormone and insulin-like growth factor I: nutritional pathophysiology and therapeutic potential. Acta Paediatr Scand Suppl 374: 119,1991.The growth hormone-insulin-like growth factor I axis has been appreciated for more than 30 years and the effects of malnutrition on this axis for more than 20 years. Over the last decade, advances in molecular biology have permitted enhanced understanding of feedback regulation between growth hormone and IGF-I at the gene level, including limited information on nutritional influences. Similarly, the availability of recombinant human growth hormone has allowed controlled clinical studies demonstrating its net anabolic actions at hypocaloric dietary energy intake levels and its ability to enhance height velocity in children with various causes of diminished growth. Although investigational use of recombinant IGF-I in humans has been limited, its actions are likely to complement those of growth hormone during periods of profound dietary energy deficit. From the information presented, two hypotheses are developed. First, recombinant IGF-I administration will enhance substrate anabolic events during the acutely malnourished state when dietary intake is severely limited. Second, administration of recombinant human growth hormone will accelerate protein anabolism and catch-up growth during the period of recovery from proteinenergy malnutrition. Given current clinical investigational tools and the availability of both recombinantly-produced hormones, these are testable hypotheses.

show abstract

“…Different studies indicate that this is related to hGH being an anabolic peptide [1, 2]. The basal metabolic rate increases during treatment [3], probably due to an increase in fat free mass and hence in metabolic activity [4]. …”

Section: Introductionmentioning

confidence: 99%

Effects of Discontinuation of Growth Hormone Treatment on Body Composition and Metabolism

Gerver¹,

Bruin²,

Waal

et al. 2000

Horm Res Paediatr

View full text Add to dashboard Cite

This study was directed to the investigation of two different aspects of growth hormone: What are the metabolic consequences following the discontinuation of treatment and are these metabolic effects correlated with the growth-promoting effects seen in the first year of treatment? The study was performed on 12 growth hormone-deficient (GHD) patients who reached their final height. Each patient was matched with a non-GHD person of the same sex and about the same age. Immediately after the discontinuation of treatment, and 6 weeks and 6 months later, the following anthropometric variables were assessed: height, weight, skinfold thicknesses (biceps, triceps, subscapular and suprailiacal), body volume (underwater weighing) and total body water (deuterium dilution). To describe energy metabolism, basal metabolic rate assessed by ventilated hood, and sleep metabolic rate assessed by respiration chamber, were studied. Body composition was calculated from weight, volume and total body water. Clear metabolic effects were found after the discontinuation of treatment in GHD children: there was a decrease in fat free mass and sleep metabolic rate. Also, a strong correlation between the above-mentioned effects and the growth-promoting effects of human growth hormone at the beginning of the treatment was observed. The fact that this correlation exists poses the interesting question of whether the results from a test treatment lasting some weeks could be used to predict the long-term effects of hGH.

show abstract

Whole Body Nitrogen Kinetics and Their Relationship to Growth in Short Children Treated with Recombinant Human Growth Hormone

Cited by 13 publications

References 38 publications

Low Prevalence of Autoantibodies to the Insulin-like Growth Factor I Receptor in Children with Short Stature

Low Prevalence of Autoantibodies to the Insulin-like Growth Factor I Receptor in Children with Short Stature

Growth Hormone and Insulin‐Like Growth Factor I: Nutritional Pathophysiology and Therapeutic Potential

Effects of Discontinuation of Growth Hormone Treatment on Body Composition and Metabolism

Contact Info

Product

Resources

About